On January 6, 2025 Electra Therapeutics, a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, reported that it will present at the 43rd annual J.P. Morgan Healthcare Conference taking place on January 13-16, 2025 in San Francisco, CA (Press release, Electra Therapeutics, JAN 6, 2025, View Source [SID1234649429]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Kathy Dong, PharmD, MBA, President and CEO of Electra Therapeutics, is scheduled to present an overview of the company and its lead drug candidate, ELA026, a first-in-class therapy in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH). The presentation details are:

Date: Thursday, January 16
Time: 8:30 a.m. PT
Location: The Westin St. Francis

Electra is advancing ELA026 as a frontline treatment for patients with sHLH, a rare, life-threatening hyperinflammatory disease for which there is no approved treatment, and the company plans to initiate a global pivotal study in 2025.